Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
99 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Closings
55 closings/delays reported.
Just In
Franklin, Granville, Vance, Warren counties under tornado warning until 1:15
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bright Minds Biosciences Inc. - common stock
(NQ:
DRUG
)
1.220
+0.020 (+1.67%)
Streaming Delayed Price
Updated: 12:43 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,082
Open
1.210
Bid (Size)
1.200 (1)
Ask (Size)
1.220 (1)
Prev. Close
1.200
Today's Range
1.202 - 1.240
52wk Range
0.9300 - 2.390
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
September 19, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
August 16, 2024
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.
Via
Benzinga
Performance
YTD
-33.65%
-33.65%
1 Month
+0.83%
+0.83%
3 Month
+12.48%
+12.48%
6 Month
+1.68%
+1.68%
1 Year
-21.79%
-21.79%
More News
Read More
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
August 15, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
August 12, 2024
Via
InvestorPlace
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
May 20, 2024
Via
InvestorPlace
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
Via
Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Via
Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
Via
Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
Via
Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
Via
Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
Via
Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
Via
Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Via
Benzinga
Exposures
Product Safety
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.